Abstract
Hormonal therapy has been the mainstay of treatment for advanced prostatic carcinoma since 1941. The first and second Veterans Administration trials cast doubt on the efficacy and advisability of early androgen deprivation. However, recent experimental and clinical studies, including a reanalysis of the VACURG data, provide a strong endorsement for early androgen ablation. A detailed risk-benefit analysis also supports this view. To affect long-term survival significantly, early hormonal therapy must be combined with novel systemic treatments effective against hormone-resistant tumor cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 15-24 |
| Number of pages | 10 |
| Journal | Urologic Clinics of North America |
| Volume | 18 |
| Issue number | 1 |
| State | Published - 1991 |
ASJC Scopus subject areas
- Urology
